Ignite Creation Date:
2025-12-25 @ 2:11 AM
Ignite Modification Date:
2026-02-20 @ 1:38 AM
Study NCT ID:
NCT00292760
Status:
COMPLETED
Last Update Posted:
2009-12-16
First Post:
2006-02-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Single-arm Phase II Study of Alemtuzumab in Combination With High-dose Methylprednisolone in CLL Patients With p53 Deletion
Sponsor:
Royal Marsden NHS Foundation Trust
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Chronic Lymphocytic Leukaemia | View |
Keywords: